Vertex Pharmaceuticals Incorporated
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $263.5M | $-112.1M | $-556.3M | $-738.6M | $-445.0M | $-107.0M | $29.6M | $-754.6M |
| Depreciation & Amortization | $61.4M | $61.4M | $62.3M | $63.3M | $48.4M | $38.2M | $35.0M | $30.5M |
| Depreciation | $61.4M | $60.8M | $60.0M | $62.3M | $47.3M | $35.7M | $28.9M | $27.9M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $293.2M | $240.6M | $231.0M | $177.5M | $127.3M | $114.3M | $118.2M | $91.1M |
| Net Cash from Operating Activities | $844.9M | $236.1M | $-365.4M | $-573.1M | $-60.7M | $267.8M | $143.7M | $-635.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $99.4M | $56.6M | $45.3M | $51.2M | $51.4M | $71.1M | $34.6M | $38.1M |
| Business Acquisitions | $0 | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-483.3M | $51.2M | $268.9M | — | — | — | — | $7.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $0 | — | — | — | — | — | — |
| Net Cash from Financing Activities | $68.4M | $133.3M | $188.9M | — | — | — | — | $425.1M |
| Net Change in Cash | $481.5M | $469.2M | $89.5M | — | — | — | — | $-203.5M |
| Free Cash Flow | $745.5M | $179.5M | $-410.7M | $-624.3M | $-112.1M | $196.7M | $109.1M | $-673.5M |